Unknown

Dataset Information

0

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.


ABSTRACT: BACKGROUND:Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic mechanisms are poorly understood. It was previously demonstrated that empagliflozin improved arterial stiffness. METHODS:Our analysis comprising 58 patients with type 2 diabetes mellitus identifies factors triggering the improvement of arterial stiffness. All patients participated in an investigator-initiated, prospective, double-blind, randomized, placebo-controlled, interventional clinical trial ( http://www.ClinicalTrials.gov : NCT02471963, registered 15th June 2015, retrospectively registered) and received either 6-weeks treatment with 25 mg empagliflozin orally once daily or placebo (crossover). Central systolic pressure and central pulse pressure were recorded by the SphygmoCor System (AtCor Medical). Now, we investigated the impact of parameters of glucose metabolism, volume status, sympathetic activation, lipids, uric acid, blood pressure and inflammation on vascular parameters of arterial stiffness using multivariate regression analysis. RESULTS:As previously reported, therapy with empagliflozin improved arterial stiffness as indicated by reduced central systolic blood pressure (113.6?±?12.1 vs 118.6?±?12.9 mmHg, p?

SUBMITTER: Bosch A 

PROVIDER: S-EPMC6440009 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.

Bosch Agnes A   Ott Christian C   Jung Susanne S   Striepe Kristina K   Karg Marina V MV   Kannenkeril Dennis D   Dienemann Thomas T   Schmieder Roland E RE  

Cardiovascular diabetology 20190329 1


<h4>Background</h4>Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic mechanisms are poorly understood. It was previously demonstrated that empagliflozin improved arterial stiffness.<h4>Methods</h4>Our analysis comprising 58 patients with type 2 diabetes mellitus identifies factors triggering the improvement of arterial stiffness. All patients participated in an investigator-initiated, prospective, double-blind, randomized, placebo-controlled, interv  ...[more]

Similar Datasets

| S-EPMC3915232 | biostudies-literature
| S-EPMC9501055 | biostudies-literature
| S-EPMC4802883 | biostudies-other
| S-EPMC6276165 | biostudies-literature
| S-EPMC10583245 | biostudies-literature
| S-EPMC5543566 | biostudies-literature
| S-EPMC5057299 | biostudies-literature
| S-EPMC4888761 | biostudies-literature
| S-EPMC8486550 | biostudies-literature
| S-EPMC8475664 | biostudies-literature